Doctors and federal investigators have spent more than a decade building a case that certain herbal and dietary supplements can cause severe, sometimes fatal, liver damage. The American Association for the Study of Liver Diseases has published practice guidance specifically addressing drug, herbal, and dietary supplement–induced liver injury, while the U.S. Drug-Induced Liver Injury Network has documented a rising share of adjudicated cases tied to these products. At least one supplement cluster in Hawaii led to acute hepatitis and fulminant liver failure, and the U.S. Department of Justice later secured felony guilty pleas from the companies behind the implicated product.
Why supplement-linked liver injury is accelerating
The core problem is not that herbs are inherently dangerous in every form. It is that modern supplement formulations often bear little resemblance to the traditional preparations they claim to replicate. A case series from the Drug-Induced Liver Injury Network described ten cases of turmeric-associated liver injury, with several of the implicated products containing piperine, a black pepper extract added to boost absorption. That bioavailability boost, designed to help the body absorb more curcumin, may also increase exposure to compounds that stress the liver. The same logic applies to concentrated green tea extracts used in weight-loss pills, which deliver far higher doses of catechins than a cup of brewed tea ever would.
This pattern suggests a testable idea: supplements that combine multiple botanicals with absorption enhancers like piperine, or that use alcohol-based extraction methods, may trigger liver injury faster than single-ingredient traditional preparations because they raise the effective dose of known hepatotoxins. The DILIN turmeric case series and the U.S. Pharmacopeia’s review of green tea extract hepatotoxicity both point in this direction, showing that concentrated, reformulated products carry risks that whole-food or beverage forms do not.
The regulatory gap makes the problem worse. Under the 1994 Dietary Supplement Health and Education Act, manufacturers do not need to prove safety or efficacy before selling supplements. The FDA can act only after harm is reported. That delay between product launch and regulatory response creates a window in which thousands of consumers may be exposed before anyone connects the dots.
DILIN data, the Hawaii outbreak, and criminal accountability
The strongest evidence comes from the Drug-Induced Liver Injury Network, a federally funded prospective study that tracks and adjudicates cases of liver injury across multiple U.S. medical centers. DILIN researchers published findings in Hepatology showing a rising share of adjudicated DILI cases attributed to herbals and dietary supplements over time, with breakdowns distinguishing bodybuilding supplements from non-bodybuilding products. The data made clear that the trend was not confined to one product category or one demographic group.
The most dramatic single episode occurred in Hawaii between May and October 2013, when the CDC, the Hawaii Department of Health, and the FDA investigated a cluster of severe acute hepatitis and fulminant liver failure tied to a weight-loss and muscle-building supplement called OxyELITE Pro. The CDC field investigation documented the outbreak, which included cases severe enough to require liver transplantation. A peer-reviewed investigation published in Clinical Toxicology detailed the case definitions, ruled out alternative causes, and confirmed the clinical severity of the cluster.
The fallout extended beyond medicine into the courts. The U.S. Department of Justice announced that five individuals and two companies pleaded guilty to felony charges in a multimillion-dollar scheme involving USPlabs products, including OxyELITE Pro and Jack3d. The charges centered on fraudulent marketing and misbranding, connecting the liver-injury timeline directly to deliberate corporate misconduct rather than an innocent manufacturing error.
Kava represents a different but related warning. The FDA issued a consumer advisory in 2002 cautioning that kava-containing dietary supplements may be associated with severe liver injury, according to the federal fact sheet from the Office of Dietary Supplements. The National Center for Complementary and Integrative Health has stated that various kava products have been linked to rare but sometimes serious or fatal liver injury, with the type of preparation, whether acetone or ethanol extract versus traditional water-based beverage, potentially influencing risk.
Gaps in the evidence and what consumers should watch
Several questions remain open. The DILIN data showing a rising proportion of supplement-linked cases was published in Hepatology, but the available evidence does not include post-2020 quantitative updates on case proportions or outcomes. Whether the trend has continued to climb, plateaued, or shifted toward new product categories is not confirmed by recent public data. Similarly, while the American Association for the Study of Liver Diseases has issued guidance on how clinicians should evaluate suspected supplement-related injury, the current draft does not include detailed, up-to-the-minute practice recommendations.
Researchers have also not fully clarified why some people develop catastrophic liver failure while many others tolerate the same product. Genetic susceptibility, underlying fatty liver disease, alcohol use, and drug–herb interactions are all plausible contributors, but definitive prospective data are sparse. Most case reports and series are retrospective, relying on patient recall and incomplete product information. Labels may omit ingredients, understate doses, or fail to disclose changes in formulation over time.
Still, the overall pattern is strong enough to support some practical guidance. First, products marketed for rapid weight loss, extreme bodybuilding, “detox,” or “liver cleanse” appear disproportionately in case series. Consumers should be especially cautious with multi-ingredient blends that promise fast results, particularly when they contain green tea extract, turmeric with piperine, kava, or other botanicals already implicated in hepatotoxicity.
Second, the route and intensity of extraction matter. Traditional preparations-such as brewed tea or water-based kava beverages-may expose the body to lower, slower doses of active constituents than capsules or liquid concentrates made with alcohol or organic solvents. While “natural” labeling can be reassuring, it does not guarantee that the preparation mimics historical use. Checking whether a supplement is a simple dried herb or a highly concentrated extract can offer at least a crude sense of relative risk.
Third, timing is critical. Many documented cases of supplement-induced liver injury present within weeks to a few months of starting a new product. Unexplained fatigue, dark urine, jaundice, right upper abdominal pain, or severe nausea in that window should prompt immediate medical evaluation and disclosure of all nonprescription products. Clinicians, for their part, need to ask specifically about supplements rather than assuming that patients will volunteer this information.
Regulatory change has been slow, but some tools already exist. The FDA’s MedWatch program allows clinicians and consumers to report suspected adverse events, creating signals that can trigger investigations. Professional societies encourage detailed case documentation, and networks like DILIN provide structured causality assessment. A recent overview of herbal and dietary supplement hepatotoxicity underscores that systematic reporting is essential to distinguish rare idiosyncratic events from emerging product-specific hazards.
Until stronger premarket testing and clearer labeling are in place, the burden of risk management falls largely on consumers and front-line clinicians. That does not mean every supplement is dangerous or that all botanical products should be avoided. It does mean that the combination of aggressive marketing, weak oversight, and biologically potent ingredients has created a predictable pattern of preventable liver injury. Recognizing that pattern-especially in products that concentrate traditional herbs into modern, highly bioavailable formulations-may be the most effective safeguard available right now.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
